Immune effectors required for the therapeutic activity of vorinostat.
作者信息
Kepp Oliver, Galluzzi Lorenzo, Kroemer Guido
机构信息
INSERM, U848; Villejuif, France ; Metabolomics and Cell Biology Platforms, Gustave Roussy; Villejuif, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers; Paris, France ; Université Paris Descartes/Paris V, Sorbonne Paris Cité; Paris, France.
Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers; Paris, France ; Université Paris Descartes/Paris V, Sorbonne Paris Cité; Paris, France ; Gustave Roussy; Villejuif, France.
出版信息
Oncoimmunology. 2013 Nov 1;2(11):e27157. doi: 10.4161/onci.27157. Epub 2013 Nov 13.
Abstract
摘要
相似文献
1
Immune effectors required for the therapeutic activity of vorinostat.
Oncoimmunology. 2013 Nov 1;2(11):e27157. doi: 10.4161/onci.27157. Epub 2013 Nov 13.
2
Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal .
J Virol. 2018 May 29;92(12). doi: 10.1128/JVI.00235-18. Print 2018 Jun 15.
3
An intact immune system is required for the anticancer activities of histone deacetylase inhibitors.
Cancer Res. 2013 Dec 15;73(24):7265-76. doi: 10.1158/0008-5472.CAN-13-0890. Epub 2013 Oct 24.
4
Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Arch Pharm (Weinheim). 2016 May;349(5):373-82. doi: 10.1002/ardp.201500472. Epub 2016 Apr 9.
5
Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.
Cancer Sci. 2014 Jun;105(6):713-22. doi: 10.1111/cas.12418. Epub 2014 May 13.
6
Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis.
J Immunother Cancer. 2020 Jan;8(1). doi: 10.1136/jitc-2019-000195. Epub 2020 Jan 2.
7
The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-γ.
J Neuroinflammation. 2012 May 30;9:113. doi: 10.1186/1742-2094-9-113.
8
The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Eur J Med Chem. 2018 Jan 1;143:1790-1806. doi: 10.1016/j.ejmech.2017.10.076. Epub 2017 Oct 31.
9
Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
J Cancer Res Clin Oncol. 2016 Feb;142(2):379-87. doi: 10.1007/s00432-015-2026-y. Epub 2015 Aug 28.
10
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
Blood. 2003 May 15;101(10):4055-62. doi: 10.1182/blood-2002-11-3514. Epub 2003 Jan 16.
引用本文的文献
1
The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
BMC Cancer. 2021 Aug 30;21(1):969. doi: 10.1186/s12885-021-08702-x.
2
Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.
Cancer Biol Ther. 2019;20(1):109-121. doi: 10.1080/15384047.2018.1507258. Epub 2018 Aug 24.
3
A broad-spectrum antibiotic, DCAP, reduces uropathogenic Escherichia coli infection and enhances vorinostat anticancer activity by modulating autophagy.
Cell Death Dis. 2018 Jul 13;9(7):780. doi: 10.1038/s41419-018-0786-4.
4
Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study.
Sci Rep. 2016 Dec 2;6:38407. doi: 10.1038/srep38407.
5
Trial Watch: Proteasomal inhibitors for anticancer therapy.
Mol Cell Oncol. 2014 Dec 1;2(2):e974463. doi: 10.4161/23723556.2014.974463. eCollection 2015 Apr-Jun.
6
An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy.
Oncoimmunology. 2014 Jul 3;3(7):e944047. doi: 10.4161/21624011.2014.944047. eCollection 2014.
7
Classification of current anticancer immunotherapies.
Oncotarget. 2014 Dec 30;5(24):12472-508. doi: 10.18632/oncotarget.2998.
8
Epigenetic enzymes are the therapeutic targets for CD4(+)CD25(+/high)Foxp3(+) regulatory T cells.
Transl Res. 2015 Jan;165(1):221-40. doi: 10.1016/j.trsl.2014.08.001. Epub 2014 Aug 15.
9
Immunogenic cell death inducers as anticancer agents.
Oncotarget. 2014 Jul 30;5(14):5190-1. doi: 10.18632/oncotarget.2266.
本文引用的文献
1
An intact immune system is required for the anticancer activities of histone deacetylase inhibitors.
Cancer Res. 2013 Dec 15;73(24):7265-76. doi: 10.1158/0008-5472.CAN-13-0890. Epub 2013 Oct 24.
2
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.
Immunity. 2013 Jul 25;39(1):74-88. doi: 10.1016/j.immuni.2013.06.014.
3
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.
Immunity. 2013 Jul 25;39(1):11-26. doi: 10.1016/j.immuni.2013.07.008.
4
Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.
Blood. 2013 Aug 1;122(5):684-93. doi: 10.1182/blood-2013-02-482513. Epub 2013 Jun 25.
5
Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines.
Cell Death Differ. 2014 Jan;21(1):50-8. doi: 10.1038/cdd.2013.60. Epub 2013 Jun 7.
6
HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.
Mol Ther. 2013 Apr;21(4):887-94. doi: 10.1038/mt.2012.265. Epub 2013 Jan 8.
7
Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects.
Oncoimmunology. 2012 Dec 1;1(9):1640-1642. doi: 10.4161/onci.21684.
8
Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies.
Oncoimmunology. 2012 Dec 1;1(9):1629-1631. doi: 10.4161/onci.21652.
9
Tumor-infiltrating B cells and T cells: Working together to promote patient survival.
Oncoimmunology. 2012 Dec 1;1(9):1623-1625. doi: 10.4161/onci.21650.
10
Radiotherapy supports protective tumor-specific immunity.
Oncoimmunology. 2012 Dec 1;1(9):1610-1611. doi: 10.4161/onci.21478.
Zotero 插件